# Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/oral-drug-products-administered-via-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations-draft-guidance-for-industry/fb28d96f-0326-4f8f-99c6-1fbcc75b445e

> FDA guidance document: Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry. Issue date: June 02, 2021. Get complete insights and analysis.

---

## Details

- Title: Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-06-02
- Comment Close Date: 2021-08-02
- Last Changed: 2022-02-01
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0391">FDA-2021-D-0391</a>

## Related Documents

- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/ind-submissions-for-individualized-antisense-oligonucleotide-drug-products-for-severely-debilitating-or-life-threatening-diseases-clinical-recommendations-draft-guidance-for-industry/2fbda0fb-0b43-42de-8bce-881ee5336b6e)
- [ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/ich-q12-implementation-considerations-for-fda-regulated-products-draft-guidance-for-industry/2c7d4c33-4495-4c29-abb1-22058de23404)